News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

pSivida Limited (PSD.AX) Provides Additional Information On Control Delivery Systems Revenues; CDS Launches Phase III Trial For Retinal Condition


10/19/2005 5:13:17 PM

PERTH, Australia--(BUSINESS WIRE)--Oct. 4, 2005--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that Control Delivery Systems in collaboration with Alimera Sciences has initiated a Phase III clinical trial to study diabetic macular edema (DME) patients treated using Medidur(TM) to deliver fluocinolone acetonide.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES